Seres Therapeutics (MCRB) Stock Forecast & Price Target

Compare

1,079 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MCRB Analyst Ratings

Moderate Buy

2 Buy

0 Hold

0 Sell

Based on 2 analysts giving stock ratings to

Seres

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MCRB Stock 12 Month Forecast

Average Price Target

$22.00

▲(18.79% Upside)

Based on 2 Wall Street analysts offering 12 month price targets for Seres Therapeutics in the last 3 months. The average price target is $22.00 with a high forecast of $22.00 and a low forecast of $22.00. The average price target represents a 18.79% change from the last price of $18.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","17":"$17","26":"$26","12.5":"$12.5","21.5":"$21.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$22.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,12.5,17,21.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.1,16.553846153846155,17.00769230769231,17.461538461538463,17.915384615384617,18.36923076923077,18.823076923076925,19.276923076923076,19.73076923076923,20.184615384615384,20.638461538461538,21.092307692307692,21.546153846153846,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.1,16.553846153846155,17.00769230769231,17.461538461538463,17.915384615384617,18.36923076923077,18.823076923076925,19.276923076923076,19.73076923076923,20.184615384615384,20.638461538461538,21.092307692307692,21.546153846153846,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.1,16.553846153846155,17.00769230769231,17.461538461538463,17.915384615384617,18.36923076923077,18.823076923076925,19.276923076923076,19.73076923076923,20.184615384615384,20.638461538461538,21.092307692307692,21.546153846153846,{"y":22,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.02,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.2,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.54,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.99,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.52,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$22.00

Lowest Price Target$22.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

John Newman

Canaccord Genuity

$22

Buy

18.79%

Upside

Reiterated

11/06/25

Canaccord Genuity Keeps Their Buy Rating on Seres Therapeutics (MCRB)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Seres Therapeutics (MCRB), Neurocrine (NBIX)3:52 PM Seres Therapeutics (NASDAQ: MCRB) Buy (1) ESG Target: NA Report THE TD COWEN INSIGHT MCRB reported Q3 financials including a cash balance of $48MM, which is expected to fund operations through Q2:26. Seres submitted a draft Ph. II protocol for SER-155 for the treatment of BSI in allo-HSCT patients and has received add'l FDA feedback and is working to finalize the protocol. Management notes several ongoing processes to secure potential funding/advancement of SER-155. SER-155 MCRB has submitted the Ph. II study protocol for lead candidate SER-155, which is being developed for infection protection in patients undergoing allo-HSCT. Based on encouraging Ph.

Keay Nakae

Chardan Capital

Hold

-67.60%

Downside

Downgraded

05/08/25

Seres Therapeutics downgraded to Neutral from Buy at ChardanSeres Therapeutics downgraded to Neutral from Buy at Chardan

Edward Tenthoff

Piper Sandler

$20

Hold

7.99%

Upside

Reiterated

03/14/25

Seres Therapeutics (MCRB) Gets a Hold from Piper Sandler

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

John Newman

Canaccord Genuity

$22

Buy

18.79%

Upside

Reiterated

11/06/25

Canaccord Genuity Keeps Their Buy Rating on Seres Therapeutics (MCRB)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

11/05/25

Keay Nakae

Chardan Capital

Hold

-67.60%

Downside

Downgraded

05/08/25

Seres Therapeutics downgraded to Neutral from Buy at ChardanSeres Therapeutics downgraded to Neutral from Buy at Chardan

Edward Tenthoff

Piper Sandler

$20

Hold

7.99%

Upside

Reiterated

03/14/25

Seres Therapeutics (MCRB) Gets a Hold from Piper Sandler

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Seres Therapeutics

1 Month

xxx

Success Rate

17/33 ratings generated profit

Average Return

+1.54%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 51.52% of your transactions generating a profit, with an average return of +1.54% per trade.

3 Months

xxx

Success Rate

15/33 ratings generated profit

Average Return

+15.25%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +15.25% per trade.

1 Year

John NewmanCanaccord Genuity

Success Rate

12/33 ratings generated profit

Average Return

+51.33%

reiterated a buy rating last month

Copying John Newman's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +51.33% per trade.

2 Years

xxx

Success Rate

11/33 ratings generated profit

Average Return

-11.72%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of -11.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MCRB Analyst Recommendation Trends

Rating

Apr 25

May 25

Aug 25

Sep 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MCRB has received 5 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MCRB average Analyst price target in the past 3 months is 22.00.

Each month's total comprises the sum of three months' worth of ratings.

MCRB Financial Forecast

MCRB Earnings Forecast

Next quarter’s earnings estimate for MCRB is -$2.11 with a range of -$2.39 to -$1.60. The previous quarter’s EPS was $0.94. MCRB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MCRB has Performed in-line its overall industry.

MCRB Sales Forecast

Next quarter’s sales forecast for MCRB is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $351.00K. MCRB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MCRB has Performed in-line its overall industry.

MCRB Stock Forecast FAQ

What is MCRB’s average 12-month price target, according to analysts?

Based on analyst ratings, Seres Therapeutics Inc.’s 12-month average price target is 22.00.

What is MCRB’s upside potential, based on the analysts’ average price target?

Seres Therapeutics Inc. has 18.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MCRB a Buy, Sell or Hold?

Seres Therapeutics Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.

What is Seres Therapeutics Inc.’s price target?

The average price target for Seres Therapeutics Inc. is 22.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $22.00. The average price target represents 18.79% Increase from the current price of $18.52.

What do analysts say about Seres Therapeutics Inc.?

Seres Therapeutics Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

How can I buy shares of MCRB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Seres Therapeutics (MCRB) Stock Forecast & Price Target

MCRB Analyst Ratings

MCRB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Seres Therapeutics

MCRB Analyst Recommendation Trends

MCRB Financial Forecast

MCRB Earnings Forecast

MCRB Sales Forecast

MCRB Stock Forecast FAQ

Detailed List of Analyst Forecasts